VTVT
vTv Therapeutics Inc.
$36.60
+0.30%
$143.7M
No data for this timeframe.
Vol
Market Cap$143.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders4 funds
Inst. Value$14.1M
Inst. Activity4 buys / 0 sells
SEC Reports1
Press Releases2
Recent Activity
Feb 26, 2026
SEC
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 developm
8-K — Impact 4/10
Inst.
FMR LLC — ADD
268,856 shares ($10.8M)
Inst.
VANGUARD GROUP INC — ADD
83,400 shares ($3.3M)
May 13, 2026
earnings
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026<
May 8, 2026
Press
vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. This is a routine com
Impact 2/10
Mar 10, 2026
Press
vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 m
Impact 6/10
Price Targets
$53.00
+44.8% upside
Strong Buy
Current $36.60
Low $44.00
Median $52.00
High $67.00
6 analysts
$44.00
$67.00
Analyst Ratings
3Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Evercore ISI Group | INITIATE | Outperform |
| Mar 11, 2026 | BTIG | REITERATE | Buy → Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jan 23, 2026 | Roth Capital | INITIATE | Buy |
| Jan 5, 2026 | TD Cowen | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.99 ▼ -6.5% | $-1.27 — $-0.61 | -8% YoY | 5 |
| Next Q | $-1.04 ▼ -18.4% | $-1.50 — $-0.64 | 4% YoY | 5 |
| Current FY | $-2.10 ▲ +18.3% | $-5.57 — $0.02 | 34% YoY | 6 |
| Next FY | $-3.89 ▼ -4.6% | $-7.81 — $-1.83 | -85% YoY | 6 |
Latest Reports
NEUTRAL
Press
2/10
vTv Therapeutics granted 39,500 stock options to two non-executive employees as inducement awards. This is a routine com
May 8, 2026
NEUTRAL
8-K
4/10
vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 developm
Feb 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $10.8M | ADD |
| VANGUARD GROUP INC | $3.3M | ADD |
| MORGAN STANLEY | $39.1K | ADD |
| BANK OF AMERICA CORP | $160.00 | DOUBLED |
4 institutional holders with $14.1M total value (353,237 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 268,856 | $10.8M | 76.1% | ADD +39.4% |
| 2 | VANGUARD GROUP INC | 83,400 | $3.3M | 23.6% | ADD +77.5% |
| 3 | MORGAN STANLEY | 977 | $39.1K | 0.3% | ADD +31.0% |
| 4 | BANK OF AMERICA CORP /DE/ | 4 | $160.00 | 0.0% | DOUBLED +300.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 192,891 | 268,856 | +39.4% | $10.8M | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 46,990 | 83,400 | +77.5% | $3.3M | 2025-Q4 |
| MORGAN STANLEY | ADD | 746 | 977 | +31.0% | $39.1K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1 | 4 | +300.0% | $160.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 12 | 1 | -91.7% | $23.00 | 2025-Q3 |
| UBS Group AG | TRIM | 4,040 | 2,847 | -29.5% | $42.7K | 2025-Q2 |
| UBS Group AG | TRIM | 7,512 | 4,040 | -46.2% | $70.0K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,146 | 746 | -34.9% | $12.9K | 2025-Q1 |
| UBS Group AG | DOUBLED | 866 | 7,512 | +767.4% | $103.7K | 2024-Q4 |
| MORGAN STANLEY | ADD | 840 | 1,146 | +36.4% | $15.8K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 3 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$53.00 mean target
+44.8% upside
Strong Buy (1.00)
$44.00 Low
$67.00 High
| Metric | Value |
|---|---|
| Current Price | $36.60 |
| Target Low | $44.00 |
| Target Mean | $53.00 |
| Target Median | $52.00 |
| Target High | $67.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.99 | $-1.27 | $-0.61 | -7.6% | -6.5% | 0↑ 1↓ | $0.0B | 0.0% | 5 |
| Next Q 2026-09-30 |
$-1.04 | $-1.50 | $-0.64 | 3.5% | -18.4% | 1↑ 1↓ | $0.0B | 0.0% | 5 |
| Current FY 2026-12-31 |
$-2.10 | $-5.57 | $0.02 | 34.4% | +18.3% | — | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-3.89 | $-7.81 | $-1.83 | -85.5% | -4.6% | 2↑ 0↓ | $0.0B | -100.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.990 | |
| 7d ago | $-0.930 | -0.060 |
| 30d ago | $-0.930 | -0.060 |
| 60d ago | $-0.930 | -0.060 |
| 90d ago | $-1.095 | +0.105 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Evercore ISI Group | INITIATE | — | Outperform |
| Mar 11, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | Roth Capital | INITIATE | — | Buy |
| Jan 5, 2026 | TD Cowen | INITIATE | — | Buy |
| Dec 19, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026</em></p>
May 13, 2026
earnings_calendar
VTVT Q1 2026 Earnings Scheduled — 2026-05-13
May 8, 2026
activist
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p>HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the de
Apr 7, 2026
other
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p>HIGH POINT, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the
Mar 18, 2026
earnings_calendar
VTVT Q4 2025 Earnings After Market Close — 2026-03-18
Mar 10, 2026
earnings
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement<br></em></p>